Initial phase II studies have also suggested activity associated with VEGF pathway and mTOR inhibitors in patients with neuroendocrine tumors of other origins including intestinal “carcinoids.” Future studies will likely define the utility of combinations of these agents in the treatments of patients with NELM. The gene discussed is VEGFA; the disease is neuroendocrine neoplasm.